Chinese Regulatory Changes Key To Life Sciences Investment Decisions – BioMedical Asia
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Regulatory reforms during the next several years will help define the next generation of winners and losers in the China life sciences industry, and investors are anxiously parsing the landscape for any signals of how the changes might play out. But trying to predict what will come next out of a notoriously opaque regulatory process is an ongoing challenge for venture capitalists and bankers alike, as evidenced by a panel discussion on Chinese investment opportunities held March 18 during the annual BioMedical Asia conference in Singapore
You may also be interested in...
Wuxi And Qiagen Form Biomarker Partnership In Shanghai
SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases
Wuxi And Qiagen Form Biomarker Partnership In Shanghai
SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases
Medical Device Sector Expected To Gain The Most From China’s Healthcare Reform
SHANGHAI- China's medical device market has reached RMB 83 billion ($12.1 billion), roughly one-eighth of the total healthcare industry, according to a report by Frost & Sullivan